Literature DB >> 19264490

Evaluation of functional MRI markers in mild cognitive impairment.

Bing Zhang1, Ming Li, Zong-Zheng Sun, Bin Zhu, Lei Yuan, Yi Wang, Yun Xu.   

Abstract

We aimed to investigate the use of advanced functional MRI (fMRI) techniques such as proton magnetic resonance spectroscopy ((1)H-MRS) and the apparent diffusion coefficient (ADC) value in diffusion weighted imaging (DWI), in the diagnosis of mild cognitive impairment (MCI). Multiple indicators were combined in order to improve the early diagnostic value of MRS and ADC. We administered MRS and DWI-ADC to 13 patients with Alzheimer's disease (AD), 9 patients with MCI, and 13 control patients. Changes in N-acetylaspartate/creatine and phosphocreatine (NAA/Cr), myoinositol/creatine (mI/Cr), and the ADC values in the hippocampus and the temporoparietal region were compared among groups. The sensitivity and specificity of different markers were analyzed individually and combined with others. All participants were evaluated by the mini mental state examination (MMSE), and the correlation between NAA/Cr, MI/Cr, ADC and the score of MMSE were analyzed separately. The NAA/Cr, mI/Cr and ADC values in the hippocampus among AD, MCI patients, and controls were significantly different (p<0.05). At a fixed specificity of 84.6%, the high sensitivity of 100% and 92.9% in differentiating AD and MCI from normal controls were obtained by combining the three indicators. The receiver operating characteristic plots illustrated that the area under the multimarker curve was the biggest among the all four curves, and the sensitivity of the multimarkers was highest. The best correlation was obtained between ADC and MMSE, rather than between NAA or mI and MMSE. Thus, we found that changes in NAA/Cr, mI/Cr and ADC in the hippocampus and the temporoparietal regions were helpful in the clinical diagnosis of MCI. Furthermore, these changes showed potential in predicting the progression of MCI to AD if the multimarkers were combined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264490     DOI: 10.1016/j.jocn.2008.07.080

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

Review 1.  The role of diffusion tensor imaging in detecting microstructural changes in prodromal Alzheimer's disease.

Authors:  Bing Zhang; Yun Xu; Bin Zhu; Kejal Kantarci
Journal:  CNS Neurosci Ther       Date:  2013-12-12       Impact factor: 5.243

Review 2.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

3.  A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice.

Authors:  Diane Jansen; Valerio Zerbi; Carola I F Janssen; Pieter J W C Dederen; Martina P C Mutsaers; Anne Hafkemeijer; Anna-Lena Janssen; Cindy L M Nobelen; Andor Veltien; Jack J Asten; Arend Heerschap; Amanda J Kiliaan
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

4.  APOE genotype and age modifies the correlation between cognitive status and metabolites from hippocampus by a 2D (1)H-MRS in non-demented elders.

Authors:  Zhenyu Yin; Wenbo Wu; Renyuan Liu; Xue Liang; Tingting Yu; Xiaoling Chen; Jie Feng; Aibin Guo; Yu Xie; Haiyan Yang; Mingmin Huang; Chuanshuai Tian; Bing Zhang; Yun Xu
Journal:  PeerJ       Date:  2015-09-17       Impact factor: 2.984

5.  Cerebral Metabolite Concentrations Are Associated With Cortical and Subcortical Volumes and Cognition in Older Adults.

Authors:  John B Williamson; Damon G Lamb; Eric C Porges; Sarah Bottari; Adam J Woods; Somnath Datta; Kailey Langer; Ronald A Cohen
Journal:  Front Aging Neurosci       Date:  2021-02-03       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.